Last month, I reported on 4 U.S. phase 3 vaccines in development which was spurred due to the release of clinical trial protocols to the public. Although no new protocols have been released, events have occurred since then that may impact the trajectory of the vaccines that launch into the market, which are discussed below.

This month’s chart adds two more phase 3 candidates. One is Novavax’s Nvx-Cov2373 vaccine. What makes this unique is that it is being tested in conjunction with a flu...